Citadel Advisors
CDIO icon

Citadel Advisors’s Cardio Diagnostics CDIO Stock Holding History

Citadel Advisors’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,858
Closed -$29.4K – 13081
2025
Q4 		$29.4K Sell
10,858
-8,662
-44% -$31.5K ﹤0.01% 12230
2025
Q3 		$78.7K Buy
+19,520
New +$77.1K ﹤0.01% 11984

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's CDIO Position: Q1 2026 in Review

Citadel Advisors sold out of Cardio Diagnostics (CDIO) in Q1 2026, closing a stake of 10,858 shares — an estimated $29.4K sold.

Citadel Advisors first reported a position in CDIO in Q3 2025 and held it in 2 quarters. The position peaked at $78.7K in Q3 2025. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • Citadel Advisors reported no remaining Cardio Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,858 Cardio Diagnostics shares in Q1 2026, an estimated $29.4K.
  • Citadel Advisors first reported a position in Cardio Diagnostics in Q3 2025 and held it in 2 quarters.
  • Citadel Advisors's Cardio Diagnostics position peaked at $78.7K in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.